Voyager Therapeutics

Voyager Therapeutics

VYGR· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -30.7% in FY2025

Alfred Sandrock, M.D., Ph.D. is the CEO of Voyager Therapeutics and was paid $2.5M in FY2025 (Dec), down 26%.

Pay$100 in the stock at the end of FY21 → $145
CEO pay is from each Voyager Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives4

See all
  1. 1Alfred Sandrock, M.D., Ph.D.FY2025
  2. 2Jacquelyn Fahey SandellFY2025
  3. 3Robin SwartzFY2025
  4. 4Toby Ferguson, M.D., Ph.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Voyager Therapeutics paid its 4 named executives $6.8M in total in FY2025 (Dec). CEO Alfred Sandrock, M.D., Ph.D. was paid $2.5M of that.

Name
Alfred Sandrock, M.D., Ph.D.Chief Executive Officer, President, and Director
Jacquelyn Fahey SandellFormer Chief Legal Officer
Robin SwartzChief Business Officer & Chief Operating Officer
Toby Ferguson, M.D., Ph.D.Former Chief Medical Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2025 (Dec) proxy of Voyager Therapeutics names 18 peer companies for pay. Among Voyager Therapeutics and these peers, CEO pay was 4th highest of 6 and total shareholder return was 4th highest of 6.

4th highest of 6in Voyager Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$2.1M$8.3M

4th highest of 6in Voyager Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$23$202

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board4

See all
  • James A. GeraghtyDirector · 9 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance (Chair)—Paid as an executive
  • Steven Hyman, M.D.Director · 8 yr on the boardIndependentAudit, Science and Technology (Chair)—Paid as an executive
  • George Scangos, Ph.D.Director · 0 yr on the boardIndependentScience and Technology—Paid as an executive
  • Grace E. Colón, Ph.D.Director · 0 yr on the boardIndependentCompensation—Paid as an executive

The board of the latest proxy (FY2023).

Activity

  1. Pay
    Voyager Therapeutics Former Chief Medical Officer pay fell 54% to $1.4M. The stock fell 31% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Voyager Therapeutics COO pay rose 17% to $1.6M. The stock fell 33% in FY2024 (Dec).
    DEF 14A
  3. Pay
    Voyager Therapeutics General counsel pay rose 20% to $1.5M. The stock fell 31% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Voyager Therapeutics General counsel pay fell 27% to $1.2M. The stock fell 33% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Voyager Therapeutics CEO pay fell 26% to $2.5M. The stock fell 31% in FY2025 (Dec).
    DEF 14A
  6. Pay
    Voyager Therapeutics CEO pay fell 57% to $3.2M. The stock rose 38% in FY2023 (Dec).
    DEF 14A
  7. Board
    Grace E. Colón, Ph.D. joined the board of Voyager Therapeutics. Grace E. Colón, Ph.D. now sits on 2 public boards.
    3
  8. Board
    George Scangos, Ph.D. joined the board of Voyager Therapeutics. George Scangos, Ph.D. now sits on 2 public boards.
    3

Filings6

See all
Proxy statementDEF 14AApr 28, 2026FY2025
Annual report10-KMar 9, 2026FY2025
Proxy statementDEF 14AApr 23, 2025FY2024
Annual report10-KMar 11, 2025FY2024
Proxy statementDEF 14AApr 25, 2024FY2023
Annual report10-KFeb 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data